Summary

In patients with relapsing-remitting multiple sclerosis (RRMS), bimonthly injection with low-dose aB-crystallin (HspB5) resulted in a decrease in gadolinium-enhancing (Gd+) lesions and clinical relapses as compared with the placebo. This article presents data from a randomized study [2011-004475-36; van Noort JM et al. ACTRIMS/ECTRIMS 2014 (poster P082)] that evaluated HspB5 for the treatment of RRMS.